Eiger BioPharmaceuticals

Business model

Clinical-stage biopharmaceutical developing treatments for rare and serious diseases, including Hepatitis Delta virus.

In brief

Developed lonafarnib, a treatment candidate for Hepatitis Delta virus infection and other rare diseases, pursuing FDA approval over more than a decade. Following a series of regulatory rejections and additional clinical setbacks for its pipeline, the company declared bankruptcy a…

See the What Happened tab for the full account.